MediWound develops bio-therapeutic solutions for tissue repair and regeneration. They market NexoBrid for removing dead tissue from burn victims. EscharEx has completed Phase II trials for chronic wound debridement. MW005 is in Phase I/II for treating low-risk basal cell carcinoma. The company was incorporated in 2000 and is headquartered in Israel.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.2 |